欧美在线观看网址 I 天堂在/线中文在线资源8 I 理发店大尺度激情视频 I 777米奇色8888狠狠俺去啦 I 成年人永久免费视频 I 国产精品成人一区二区艾草 I 欧美成人综合 I 福利社一区二区 I 范冰冰男人装 I 午夜精品av I 成人在线免费观看av I 亚洲视频在线免费观看 I 国产成人福利在线 I 久久成人麻豆午夜电影 I 亚洲国产精品嫩草影院久久 I 偷偷撸在线 I 无人区国产成人久久三区 I 狼色视频 I 日韩欧美a级片 I 99国产精品久久久久久久床豆 I 免费无码久久成人影片 I 国产97视频 I 久久久国产精品视频 I 青青草原免费视频在线观看 I 久久久极品 I 亚州国产精品 I 污视频网站在线观看 I 日韩精品中字

On October 27, the intelligent factory project of Anti-tumor high-end complex preparation of HOdo Group was officially started, marking the transformation and upgrading of HOdo's big health industry and means that the intelligent manufacturing of HOdo Group has reached a new stage.

Haijiang Zhou said in his speech that in the face of the current complex situation, HOdo Group's response is to actively practice the new development concept, accelerate the evolution & upgrading of the enterprise, and continue to promote the construction of intelligent, green, online, high-end, international and standardized "Six." This project is an important embodiment of the Group's acceleration of intelligent and high-end development. It is reported that the project is a key project to enhance the international competitiveness of the enterprise, with a total investment of 520 million yuan and an annual output of 20 million bottles of anti-tumour injections and 100 million tablets of anti-tumour solid preparations, realizing an output value of more than 1.5 billion yuan and an annual profit of 300 million yuan. The project will construct three production lines for anti-tumour preparations, including a non-final sterilization production line for anti-tumour injections, a final sterilization production line for anti-tumour injections, and an anti-tumour solid preparation production line, which all in accordance with Chinese GMP, FDA, EU and other international first-class standards, all the use of international first-class intelligent equipment and facilities, combined with the CONCEPT of QbD design and construction of the top factory facilities, CIP/SIP(VHP sterilization) and fully closed (Isolator) sterile filling line. The advanced fully sealed RTP system transfers sterile materials, and the computerized system covers the entire isolator filling line, sterile transfer and lyophilization. The whole production process is automatic and intelligent. The project is expected to be produced in the first half of 2023, significantly improving the Group's pharmaceutical production capacity, technology level, and product market competitiveness.